Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Clinical application of D-dimer in Kawasaki Disease

가와사끼병에서 D-dimer의 임상적 응용

  • Han, Jae Joon (Department of Pediatrics, College of Medicine, Korea University) ;
  • Ko, Hong Ki (Department of Pediatrics, College of Medicine, Korea University) ;
  • Yoo, Young (Department of Pediatrics, College of Medicine, Korea University) ;
  • Lee, JungHwa (Department of Pediatrics, College of Medicine, Korea University) ;
  • Lee, Kwang Chul (Department of Pediatrics, College of Medicine, Korea University) ;
  • Son, Chang Sung (Department of Pediatrics, College of Medicine, Korea University) ;
  • Lee, Joo Won (Department of Pediatrics, College of Medicine, Korea University)
  • 한재준 (고려대학교 의과대학 소아과학교실) ;
  • 고홍기 (고려대학교 의과대학 소아과학교실) ;
  • 유영 (고려대학교 의과대학 소아과학교실) ;
  • 이정화 (고려대학교 의과대학 소아과학교실) ;
  • 이광철 (고려대학교 의과대학 소아과학교실) ;
  • 손창성 (고려대학교 의과대학 소아과학교실) ;
  • 이주원 (고려대학교 의과대학 소아과학교실)
  • Received : 2006.10.17
  • Accepted : 2006.12.15
  • Published : 2007.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Vascular endothelial cell damage and alteration of a fibrinolytic system was suggested to play a role in the development of coronary artery abnormalities in Kawasaki disease (KD). D-dimer is one of the markers of endothelial damage and fibrinolysis. We evaluated the clinical usefulness of D-dimer to differentiate KD from other febrile diseases and predict coronary artery abnormalities in KD. Methods : Sixty eight patients diagnosed as KD and twenty eight patients presented with acute febrile illnesses other than KD from September 2005 to July 2006 were included. Blood levels of D-dimer and various inflammatory markers were measured before treatment and the clinical course of KD was followed. Serial echocardiography was performed at the onset of disease and thereafter at a monthly interval for at least 2 months. Results : KD patients showed a higher D-dimer level than febrile controls, but the difference was not significant ($1.21{\pm}0.77{\mu}g/mL$ vs $0.92{\pm}0.71{\mu}g/mL$, P=0.083). Neither was the difference between KD patients who had coronary artery abnormalities and those who had not ($1.49{\pm}0.98{\mu}g/mL$ vs $1.15{\pm}0.71{\mu}g/mL$, P=0.169). D-dimer was significantly correlated with other inflammatory markers, such as C-reactive protein and erythrocyte sedimentation rate in both KD patients and febrile controls. Conclusion : D-dimer was not specific for KD. But it may be useful as an inflammatory marker to assess the severity of KD.

목 적: 혈관내피 손상과 섬유소 용해계의 표지자 중 하나인 D-dimer가 가와사끼병의 감별진단과 관상동맥 병변의 예측인자로서 유용한지를 알아 보고자 하였다. 방 법: 2005년 9월부터 2006년 6월까지 고려대학교 의료원에 입원한 가와사끼병 환아68명(환아군)과 급성 열성질환 환아 28명(대조군)을 대상으로 혈액검사를 시행하여 D-dimer, CRP, ESR, 전해질 및 기타 생화학적 검사를 시행하였으며, 환아군은 급성기와 발병 4, 8주에 심장초음파를 시행하여 관상동맥 병변 여부를 검사하였다. 결 과: D-dimer는 환아군에서 대조군보다 높았으나 유의하지 않았으며($1.21{\pm}0.77{\mu}g/mL$ vs $0.92{\pm}0.71{\mu}g/mL$, P=0.083), 관상동맥 이상을 보였던 군에서 관상동맥 이상이 없었던 군보다 높았으나 역시 유의하지 않았다($1.49{\pm}0.98{\mu}g/mL$ vs $1.15{\pm}0.71{\mu}g/mL$, P=0.169). D-dimer는 환아군과 대조군을 포함한 분석에서 ESR(r=0.203, P<0.05), CRP(r=0.349, P<0.001), 백혈구 수(r=0.275, P<0.01)와 유의한 상관관계를 보였다. 결 론: D-dimer는 가와사끼병에 특이적이지 못하여 다른 열성질환과의 감별진단이나 관상동맥 이상을 예측하는데 유용하지는 못하지만 염증의 정도를 나타내는 비특이인자로서 가와사끼병 환아의 중증도 평가에 보조적 인자가 될 수 있을 것이다.

Keywords

References

  1. Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome. A skin biopsy study of 27 patients. Eur J Pediatr 1978;129: 17-27 https://doi.org/10.1007/BF00441370
  2. Brendel-Muller K, Hahn A, Schneppenheim R, Santer R. Laboratory signs of activated coagulation are common in Henoch-Schonlein purpura. Pediatr Nephrol 2001;16:1084-8 https://doi.org/10.1007/s004670100033
  3. Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996;75:892-8
  4. Sakai M, Asayama K, Otabe T, Kohri T, Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin Appl Thromb Hemost 2001;7: 214-8 https://doi.org/10.1177/107602960100700306
  5. Imamura T, Yoshihara T, Yokoi K, Nakai N, Ishida H, Kasubuchi Y. Impact of increased D-dimer concentrations in Kawasaki disease. Eur J Pediatr 2005;164:526-7 https://doi.org/10.1007/s00431-005-1699-7
  6. Lin MT, Tsao LY, Cheng ML, Chang YJ, Chiu HY, Chen HN, et al. Absence of hypercoagulability in acute Kawasaki disease. Pediatr Int 2005;47:126-31 https://doi.org/10.1111/j.1442-200x.2005.02025.x
  7. Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo 1984
  8. Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990;1:225-35
  9. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Jr., Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797- 803
  10. Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/ fibrin degradation products in hypercoagulable states. Br J Haematol 1989;71:65-70 https://doi.org/10.1111/j.1365-2141.1989.tb06276.x
  11. Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard ME. Usefulness of D-dimer, blood gas, and respiratory rate measurements for excluding pulmonary embolism. Thorax 1998;53:830-4 https://doi.org/10.1136/thx.53.10.830
  12. de Moerloose P, Desmarais S, Bounameaux H, Reber G, Perrier A, Dupuy G, et al. Contribution of a new, rapid, individual and quantitative automated D-dimer ELISA to exclude pulmonary embolism. Thromb Haemost 1996;75:11-3
  13. Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61 https://doi.org/10.1007/BF00920793
  14. Burns JC, Glode MP, Clarke SH, Wiggins J, Jr., Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 1984;105:206-11 https://doi.org/10.1016/S0022-3476(84)80114-6
  15. Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, et al. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res 2003;53:983-8 https://doi.org/10.1203/01.PDR.0000061566.63383.F4
  16. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33 https://doi.org/10.1542/peds.2004-2182
  17. Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, et al. Elevated levels of high-sensitivity Creactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38-43 https://doi.org/10.1161/01.CIR.0000151311.38708.29
  18. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000;137: 177-80 https://doi.org/10.1067/mpd.2000.107890
  19. Hidaka T, Nakano M, Ueta T, Komatsu Y, Yamamoto M. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr 1983;102:94-6 https://doi.org/10.1016/S0022-3476(83)80300-X